Benzopyrazines, commonly known as quinoxaline derivatives, are a significant group of heterocyclic compounds. Due to the vast range of biological activities that quinoxalines exhibit, they have received a lot of interest. Derivatives of quinoxaline (benzopyrazine), which contain the pyrazoline ring structure, are a class of physiologically active compounds. They demonstrated broad range of biological activates ; anticancer, anti-inflammatory, antibacterial, antidepressant, hypoglycemic, hypotensive, and antihistamic because of their ability to serve as protein kinase inhibitors, they are regarded as crucial starting point for anticancer medicines. Since quinoxalines have been shown to be selective ATP-competitive inhibitors of numerous kinases, including the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), proto-oncogene tyrosine-protein kinase (Src), c-Met proto-oncogene (c-Met kinase), epidermal growth factor receptor, Janus kinase receptor (JAK-2), FMs-related tyrosine kinase 3 (FLT-3) and cyclin dependent kinase (CDK1,2,4,6). Quinoxaline derivatives' chemistry and their possible anti-tyrosine kinase effects are the main topics of this paper.